Janux Therapeutics, Inc. Stock: price and insider trades · United States

Janux Therapeutics, Inc. is a US-listed clinical-stage biopharmaceutical company trading on the NASDAQ under the ticker JANX. Headquartered in San Diego, California, and incorporated in Delaware in June 2017, the company focuses on next-generation immunotherapies for cancer and, more recently, autoimmune disease. Its strategy is built around proprietary platforms designed to conditionally activate T cells in the tumor microenvironment, with the goal of preserving anti-tumor potency while reducing the systemic toxicity that has limited many earlier immunotherapy approaches. Janux’s core technology stack includes TRACTr (Tumor Activated T Cell Engager), TRACIr (Tumor Activated Immunomodulator), and ARM (Adaptive Immune Response Modulator), which together form the basis of a platform-driven pipeline strategy.

From a business perspective, Janux remains a development-stage company with no marketed products and no product revenue to date. Its operating model is centered on R&D, translational work, and early clinical execution. The company’s lead historical program has been JANX007, a PSMA-targeted TRACTr being evaluated in prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Janux also advanced JANX008, an EGFR-targeted candidate in multiple solid tumors, while expanding its pipeline with JANX011, the first clinical asset from its ARM platform, and JANX014. The company has also highlighted autoimmune disease as a longer-term expansion opportunity, broadening its addressable market beyond oncology. In 2026, Janux announced discontinuation of the JANX008 clinical program, a reminder that pipeline management remains highly data-dependent in this sector.